Spots Global Cancer Trial Database for Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
Official Title: Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study
Study ID: NCT03478488
Conditions
Study Description
Brief Summary: This is a randomized, open-label, parallel-group multi-center study of Phase 3 study to assess the efficacy and safety of KN035 compared to standard of care (SOC) Gemcitabine-based chemotherapies in the treatment of participants with previously untreated locally advanced or metastatic biliary tract cancer. The primary hypothesis of this study is that participants will have a longer overall Survival (OS) when treated with combined therapy than SOC.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Chinese people's liberation army (PLA) 81hospital, Nanjing, Jiangsu, China
Contact Details
Name: Shukui Qin
Affiliation: The Chinese people's liberation army (PLA) 81 hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
